Gotrade News - First-quarter 2026 earnings produced record revenue prints across multiple Wall Street names, led by Eli Lilly (LLY) with a 56% year-over-year revenue surge. The strength spread across pharma, infrastructure, and health technology in a single reporting day.
Several companies raised full-year guidance, signaling momentum extending into the second half. Investors read the prints as further evidence that the recession narrative this year is increasingly hard to defend.
Key Takeaways
- Eli Lilly posted Q1 revenue of $19.8B (+56% YoY) and GAAP EPS up 170%, lifted by FDA approval of Foundayo.
- Quanta Services reported record revenue of $7.87B and raised full-year guidance to $34.7-35.2B.
- MasTec hit $3.8B (+34%) while DexCom grew 15% to $1.19B in the same quarter.
Eli Lilly Leads on Foundayo
Eli Lilly reported Q1 2026 revenue of $19.8 billion, up 56% year-over-year on volume growth of 65%. GAAP EPS hit $8.26, up 170% from the prior year.
FDA approval of Foundayo (orforglipron) was the headline catalyst, making it the only approved GLP-1 pill without food or water restrictions. Mounjaro printed $8.7 billion and Zepbound $4.1 billion in worldwide revenues.
Management raised 2026 revenue guidance by $2 billion to a range of $82-85 billion. Non-GAAP EPS guidance moved to $35.50-37.00 per share.
Quanta Services Hits Record Backlog
Quanta Services reported record Q1 revenue of $7.87 billion, up from $6.23 billion year-over-year. Adjusted EBITDA hit $686.4 million and adjusted diluted EPS came in at $2.68.
Total backlog reached $48.5 billion and remaining performance obligations stood at $26.2 billion. CEO Duke Austin highlighted the company's positioning at the intersection of utility, generation, and large-load markets, addressing a $2.4 trillion total addressable market.
Management lifted full-year guidance to revenue of $34.7-35.2 billion and adjusted diluted EPS of $13.55-14.25. The target is sustained double-digit earnings growth through the decade.
DexCom and MasTec Round Out the Tape
DexCom reported Q1 revenue of $1.19 billion with 15% growth on the period. DXCM continues to show resilient demand for continuous glucose monitoring devices despite competitive pressure.
MasTec (MTZ) printed record revenue of $3.8 billion with 34% growth, driven by transmission and clean infrastructure exposure. Engie reported a 15% profit decline on weaker energy sales, underscoring the divergence within traditional energy.
What To Watch
Watch whether the raised guidance holds after Q2 reporting concludes. Many names raise expectations on a first record print and then normalize as base effects fade.
Healthcare and infrastructure look most defensive against macro softening here. Long-duration investors will read the Q1 prints as confirmation that GLP-1 and AI infrastructure themes are still intact.
